Skip to main content

Table 2 RWE studies included in the NMA and main data extracted per treatment

From: The inclusion of real world evidence in clinical development planning

Study Treatments No. of subjects (N) No. of Relapses Person years EDSS
Lanzillo (2012) [39] Natalizumab 42 10 42 3.5
Rebif 44 42 23 42
Limmroth (2007) [40] Avonex 1094 1116 2188 2.62
Betaferon 1034 1075 2068
Rebif 22 555 588 1110
Rebif 44 185 233 370
Halpern (2011) [41] Natalizumab 288 21 72  
Avonex 151 7 38
Rebif 22 329 22 82
Betaferon 144 11 36
Glatiramer acetate 469 25 117
Patti (2006) [42] Betaferon 114 137 570 2.2
Avonex 37 50 185
Rebif 22 17 35 85
Río (2005) [43] Placebo 107 288 356 2.73
Glatiramer acetate 101 204 334
Haas and Firzlaff (2005) [44] Avonex 79 109 158 2.2
Betaferon 77 123 154 2.28
Glatiramer acetate 79 56 158 1.98
48 59 96 2.36
Khan et al. (2001) [45] Placebo 15 23 23 2.63
Avonex 34 41 51 2.71
Betaferon 34 28 51 2.6
Glatiramer acetate 39 29 59 2.64
Trojano et al. (2003) [46] Betaferon 209 136 418 2.5
Avonex 169 120 338 2.4
Carra et al. (2003) [47] Avonex 26 14 35 2.02
Rebif 44 20 2 27 2.08
Betaferon 20 11 27 3.31
Glatiramer acetate 30 8 40 2.45